Mabion (WAR:MAB) FCF Yield % : -15.39 (As of Jun. 03, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Mabion FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Mabion's Trailing 12-Month Free Cash Flow is zł-41.4 Mil, and Market Cap is zł269.3 Mil. Therefore, Mabion's FCF Yield % for today is -15.39%.

The historical rank and industry rank for Mabion's FCF Yield % or its related term are showing as below:

WAR:MAB' s FCF Yield % Range Over the Past 10 Years
Min: -31.37 Med: -7.6 Max: 25.14
Current: -15.39

During the past 13 years, the highest FCF Yield % of Mabion was 25.14%. The lowest was -31.37%. And the median was -7.60%.

WAR:MAB's FCF Yield % is ranked worse than
51.48% of 1552 companies
in the Biotechnology industry
Industry Median: -14.1 vs WAR:MAB: -15.39

Mabion's FCF Margin % for the quarter that ended in Mar. 2024 was 45.12%.

Mabion FCF Yield % Historical Data

The historical data trend for Mabion's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion FCF Yield % Chart

Mabion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-4.06

-13.55

-6.53

6.51

-13.75

Mabion Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															22.82	-45.87	-8.42	-27.97	23.28

Competitive Comparison of Mabion's FCF Yield %

For the Biotechnology subindustry, Mabion's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabion's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Mabion's FCF Yield % falls into.

Mabion FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Mabion's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-40.33	/	293.345745
	=	-13.75%

Mabion's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	15.33	*	4	/	263.44549
	=	23.28%

Mabion FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Mabion FCF Yield % Related Terms

Thank you for viewing the detailed overview of Mabion's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabion (WAR:MAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

272:Germany

Address

ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050

Website

https://www.mabion.eu

Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.